The Claim
In patients with non-obstructive coronary artery disease, statin use is associated with a lower proportion of noncalcified fibrous plaque compared to non-use, indicating a shift in plaque composition toward more stable phenotypes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Patients with non-obstructive coronary artery disease who take statins have a lower amount of soft, unstable plaque in their arteries compared to those who do not take statins.
See the scientific wording
In patients with non-obstructive coronary artery disease, statin use is associated with a lower proportion of noncalcified fibrous plaque compared to non-use, suggesting a shift in plaque composition toward more stable phenotypes.
Statin use lowers cholesterol in the blood, which reduces fatty buildup inside artery walls. This causes immune cells and muscle cells in the plaque to change into bone-like cells that deposit calcium, turning soft, unstable plaque into harder, more stable plaque.
What the research says
1 studyPeople with mild heart disease who take statins tend to have more hard, calcium-rich plaque and less soft, fatty plaque than those who don’t take statins — and harder plaque is less likely to rupture and cause heart attacks.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.